Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kuwait cohort of the A1chieve study.

Daban A, Ali HH.

Indian J Endocrinol Metab. 2013 Nov;17(Suppl 2):S465-8. doi: 10.4103/2230-8210.122080.

PMID:
24404483
2.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG).

Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20.

PMID:
22018631
3.

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.

Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Breast Cancer Res Treat. 2012 Jan;131(1):295-306. doi: 10.1007/s10549-011-1741-6. Epub 2011 Sep 4.

PMID:
21892704
4.

Breast cancer care compared with clinical Guidelines: an observational study in France.

Lebeau M, Mathoulin-Pélissier S, Bellera C, Tunon-de-Lara C, Daban A, Lipinski F, Jaubert D, Ingrand P, Migeot V; REPERES Group.

BMC Public Health. 2011 Jan 20;11:45. doi: 10.1186/1471-2458-11-45.

PMID:
21251274
5.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS.

N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818.

PMID:
19692688
6.

Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.

Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group; BIG 1-98 Collaborative Group.

Clin Trials. 2009 Jun;6(3):272-87. doi: 10.1177/1740774509105380.

PMID:
19528136
7.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Ann Oncol. 2009 Sep;20(9):1489-98. doi: 10.1093/annonc/mdp033. Epub 2009 May 27.

PMID:
19474112
8.

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98.

J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829. Epub 2008 Nov 3.

PMID:
18981464
9.

[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].

Boige V, Barbare JC, Rosmorduc O; Groupe de travail carcinome hépatocellulaire Prodige-Afef.

Gastroenterol Clin Biol. 2008 Jan;32(1 Pt. 1):3-7. doi: 10.1016/j.gcb.2007.11.001. Epub 2008 Mar 4. French. No abstract available.

PMID:
18341970
10.

Quality of surgery in T3-4 rectal cancer: involvement of circumferential resection margin not influenced by preoperative treatment. Results from EORTC trial 22921.

den Dulk M, Collette L, van de Velde CJ, Marijnen CA, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bosset JF; EORTC Radiation Oncology Group.

Eur J Cancer. 2007 Aug;43(12):1821-8. Epub 2007 Jul 12.

PMID:
17627809
11.

[Hospital pathway of patients with breast cancer].

Boinot L, Gautreau G, Defossez G, Daban A, Bourgeois H, Migeot V, Ingrand P.

Rev Epidemiol Sante Publique. 2007 Apr;55(2):142-8. French.

PMID:
17434281
12.

Chemotherapy with preoperative radiotherapy in rectal cancer.

Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC; EORTC Radiotherapy Group Trial 22921.

N Engl J Med. 2006 Sep 14;355(11):1114-23. Erratum in: N Engl J Med. 2007 Aug 16;357(7):728.

PMID:
16971718
13.

[Mesenteric stromal tumor revealed as a complication of colonoscopy].

Vuillemin E, Croquet V, Diaz De Cério J, El Khourge G, Ouali L, Daban A.

Gastroenterol Clin Biol. 2006 Jan;30(1):152-3. French. No abstract available.

PMID:
16514400
14.

Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.

Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Briffaux A, Collette L.

J Clin Oncol. 2005 Aug 20;23(24):5620-7. Epub 2005 Jul 11.

PMID:
16009958
15.

Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma.

Bourgeois H, Billiart I, Chabrun V, Chieze S, Lemerre D, Germain T, Ferrand V, Meurice JC, Daban A, Tourani JM.

Am J Clin Oncol. 2004 Feb;27(1):89-95.

PMID:
14758140
16.

Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group.

Bosset JF, Calais G, Daban A, Berger C, Radosevic-Jelic L, Maingon P, Bardet E, Pierart M, Briffaux A; EORTC Radiotherapy Group.

Eur J Cancer. 2004 Jan;40(2):219-24.

PMID:
14728936
17.

[Chemoradiotherapy in the adjuvant treatment of gastric adenocarcinomas: real progress?].

Mineur L, Lacaine F, Ychou M, Bosset JF, Daban A.

Cancer Radiother. 2002 Nov;6 Suppl 1:13s-23s. Review. French.

PMID:
12587378
18.

Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.

Gaci Z, Bouin-Pineau MH, Gaci M, Daban A, Ingrand P, Métayé T.

Int J Oncol. 2001 Apr;18(4):793-800.

PMID:
11251176
19.

[Retrospective analysis of results of treatment of 91 oral cavity cancers from 1982 to 1992].

Pradier O, Hummers-Pradier E, Gaci Z, Jadaud D, Descrozailles JM, Gesta P, Germain T, Daban A, Hess CF.

Cancer Radiother. 2000 Jan-Feb;4(1):32-9. French.

PMID:
10742807
20.

Accuracy of alignment in breast irradiation: a retrospective analysis of clinical practice.

Pradier O, Schmidberger H, Weiss E, Bouscayrol H, Daban A, Hess CF.

Br J Radiol. 1999 Jul;72(859):685-90.

PMID:
10624326

Supplemental Content

Loading ...
Support Center